Evidence Level
Royal Jelly is a nutrient-rich substance produced by honeybees, containing bioactive compounds such as 10-hydroxy-2-decenoic acid (10-HDA). Research has explored its potential benefits in managing menopausal symptoms, lipid metabolism, and skin health. A systematic review and meta-analysis by Ferraz et al. (2026) involving 471 postmenopausal women found that royal jelly supplementation significantly improved symptoms compared to placebo, with moderate-quality evidence supporting its efficacy. Guo et al. (2007) reported that a daily dose of 6g reduced total cholesterol and LDL in mildly hypercholesterolemic adults over six weeks. For skin health, Park et al. (2011) demonstrated improved hydration and wrinkle reduction with oral supplementation.
However, limitations include small sample sizes, predominantly Japanese populations, and variability in royal jelly preparations. Safety concerns arise from case reports of anaphylaxis, including fatal outcomes. While some studies suggest potential benefits for glycemic control and lipid profiles in individuals with diabetes (Maleki et al., 2019), others found no significant effects on glycemic markers (Mahboobi et al., 2019). Additionally, preclinical data reviewed by Aavani et al. (2024) suggest that low doses of royal jelly may reduce breast cancer risk by modulating hormone levels, though clinical evidence is lacking.
Overall, while Royal Jelly shows promise in several areas, further research with larger, diverse populations and standardized preparations is needed to confirm its benefits and safety profile.